Sage Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2010. The company focuses on developing and commercializing innovative medicines for brain health disorders, with a strong emphasis on maternal mental health. Sage's mission is to create life-changing treatments that help individuals thrive, integrating insights from patients and care partners throughout the research and commercialization process.

The company has made significant strides in treating postpartum depression (PPD) with its flagship product, Zulresso (brexanolone), which was the first FDA-approved treatment specifically for PPD, approved in 2019. In 2023, Sage received FDA approval for Zuranolone (Zurzuvae), another PPD treatment developed in collaboration with Biogen. Sage Therapeutics also has a pipeline of compounds targeting various brain health disorders, supported by strategic partnerships that enhance its development capabilities. The company is committed to engaging with patients and healthcare providers to ensure its treatments effectively address real-world needs.